Antithrombotic activity of the novel oral anticoagulant, Tecarfarin [Sodium 3-[4-((1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yloxy) carbonyl) benzyl]-2-oxo-2H-chromen-4-olate] in animal models.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Thrombosis Research

• Publication date

  2010-11-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.thromres.2010.08.025PMID 20869102
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The First Evaluation of a Novel Vitamin K Antagonist, Tecarfarin (ATI-5923), in Patients With Atrial Fibrillation

  2009cited by this paper
• Effect of tecarfarin, a novel vitamin K epoxide reductase inhibitor, on coagulation in beagle dogs

  2009cited by this paper
• Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

  2008cited by this paper
• Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

  2008cited by this paper
• Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

  2008cited by this paper
• The Potential for Interaction between Warfarin and Coprescribed Medication

  2008cited by this paper
• Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation

  2007cited by this paper
• Potential Drug–Drug Interactions in the Outpatient Setting

  2006cited by this paper
• Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, P

  2006cited by this paper
• Impact of age, CYP2C9 genotype and concomitant medication on the rate of rise for prothrombin time during the first 30 days of warfarin therapy.

  2005cited by this paper
• Systematic overview of warfarin and its drug and food interactions.

  2005cited by this paper
• Frequency and Causes of Overanticoagulation and Underanticoagulation in Patients Treated with Warfarin

  2004cited by this paper
• Mechanism of warfarin potentiation by amiodarone: Dose — and concentration — Dependent inhibition of warfarin elimination

  2004cited by this paper
• Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis.

  2004cited by this paper
• The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

  2004cited by this paper
• Frequency of Concurrent Use of Warfarin with Potentially Interacting Drugs

  2004cited by this paper
• The benefit‐to‐risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model

  2003cited by this paper
• Role of Desethylamiodarone in the Anticoagulant Effect of Concurrent Amiodarone and Warfarin Therapy

  2001cited by this paper
• Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.

  2001cited by this paper
• The sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. American College of Chest Physicians.

  2001cited by this paper
• The antithrombotic effects of CI-1031 (ZK-807834) and enoxaparin in a canine electrolytic injury model of arterial and venous thrombosis.

  2001cited by this paper
• Hirudin causes more bleeding than heparin in a rabbit ear bleeding model.

  1998cited by this paper
• Interaction of low molecular weight heparin with ketorolac.

  1996cited by this paper
• Warfarin-induced changes in procoagulant and anticoagulant proteins.

  1995cited by this paper
• Interactions of Warfarin with Drugs and Food

  1994cited by this paper
• The mechanism of the interaction between amiodarone and warfarin in humans

  1992cited by this paper
• Interaction of amiodarone with racemic warfarin and its separated enantiomorphs in humans

  1987cited by this paper
• The biochemical basis of warfarin therapy.

  1987cited by this paper
• The warfarin‐sulfinpyrazone interaction: stereochemical considerations

  1986cited by this paper
• Dose-dependent antithrombotic effect of warfarin in rabbits.

  1983cited by this paper
• Stereoselective interaction of trimethoprim-sulfamethoxazole with the separated enantiomorphs of racemic warfarin in man.

  1980cited by this paper
• An Assay of the Antithrombotic Action of Warfarin: Its Correlation with the Inhibition of Stasis Thrombosis in Rabbits

  1978cited by this paper
• Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition.

  1978cited by this paper
• The stereoselective interaction of warfarin and metronidazole in man.

  1976cited by this paper
• Warfarin. Stereochemical aspects of its metabolism and the interaction with phenylbutazone.

  1974cited by this paper

• OPTIMIZATION OF VITAMIN K ANTAGONISTS LABORATORY MONITORING AND TECARFARIN : TWO FUTURE SOLUTIONS FOR ORAL ANTICOAGULANT TREATMENT ?

  2023cites this paper
• OPTIMIZATION OF VITAMIN K ANTAGONISTS LABORATORY MONITORING AND TECARFARIN : TWO FUTURE SOLUTIONS FOR ORAL ANTICOAGULANT TREATMENT ?

  2023cites this paper
• Functional characterization and correlation analysis of phenylalanine ammonia-lyase (PAL) in coumarin biosynthesis from Peucedanum praeruptorum Dunn.

  2019cites this paper
• New anticoagulants for venous thromboembolism and atrial fibrillation: what the future holds

  2018cites this paper
• Biological importance of structurally diversified chromenes.

  2016cites this paper
• Design, Synthesis, and In Vitro Evaluation of Novel 3, 7‐Disubstituted Coumarin Derivatives as Potent Anticancer Agents

  2015cites this paper
• Recent advances in the design and development of soft drugs.

  2014cites this paper
• A comparative study of the molecular structure, lipophilicity, solubility, acidity, absorption and polar surface area of coumarinic anticoagulants and direct thrombin inhibitors

  2014cites this paper
• Determination of the warfarin inhibition constant Ki for vitamin K 2,3-epoxide reductase complex subunit-1 (VKORC1) using an in vitro DTT-driven assay.

  2013cites this paper
• Novel antithrombotic agents & future directions

  2012cites this paper
• 5. Soft Drugs

  2012cites this paper
• [Old and new oral anticoagulants. Pharmacological perspective].

  2012cites this paper
• Antitumor agents 292. Design, synthesis and pharmacological study of S- and O-substituted 7-mercapto- or hydroxy-coumarins and chromones as potent cytotoxic agents.

  2012cites this paper
• A Systematic Review of the Literature

  2012cites this paper
• Emerging anticoagulants.

  2012cites this paper
• Velhos e novos anticoagulantes orais. Perspetiva farmacológica

  2012cites this paper
• Battle of oral anticoagulants in the field of atrial fibrillation scrutinized from a clinical practice (the real world) perspective

  2011cites this paper